GRI Bio
4 hedge funds and large institutions have $140K invested in GRI Bio in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
21% less capital invested
Capital invested by funds: $177K → $140K (-$37.5K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
54.58% less ownership
Funds ownership: 55.4% → 0.81% (-55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$250K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$88.1K |
| 3 |
BlackRock
New York
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$143K |
| 2 |
HF
HRT Financial
New York
|
-$14K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$9.65K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$3 |
GRI Hedge Fund Activity: Q2 2024 in Review
4 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q2 2024, worth a combined $140K — down 21% from $177K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GRI and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $250K. The largest seller was Altium Capital Management, exiting entirely with an estimated $143K sold.
- 4 institutional investors held GRI Bio (GRI) as of Q2 2024, down from 5 in Q1 2024.
- Funds reported $140K of GRI Bio stock for Q2 2024, down 21% quarter-over-quarter.
- 2 funds opened new GRI Bio positions in Q2 2024 and 3 closed out, a net change of -1 holder.
- The largest GRI Bio buyer in Q2 2024 was Armistice Capital, an estimated $250K added.
- The largest GRI Bio seller in Q2 2024 was Altium Capital Management, an estimated $143K sold.
Based on aggregated 13F filings for Q2 2024.